The latest price target for ALPINE IMMUNE SCIENCES INC COM (NASDAQ:ALPN) was reported by Wedbush on May 16, 2024. The analyst firm set a price target for $65.00 expecting ALPN to fall to within 12 months (a possible NaN% downside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for ALPINE IMMUNE SCIENCES INC COM (NASDAQ:ALPN) was provided by Wedbush, and ALPINE IMMUNE SCIENCES INC COM reiterated their neutral rating.

There is no last upgrade for ALPINE IMMUNE SCIENCES INC COM

The last downgrade for ALPINE IMMUNE SCIENCES INC COM happened on April 16, 2024 when TD Cowen changed their price target from N/A to N/A for ALPINE IMMUNE SCIENCES INC COM.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALPINE IMMUNE SCIENCES INC COM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALPINE IMMUNE SCIENCES INC COM was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.

While ratings are subjective and will change, the latest ALPINE IMMUNE SCIENCES INC COM (ALPN) rating was a reiterated with a price target of $0.00 to $65.00. The current price ALPINE IMMUNE SCIENCES INC COM (ALPN) is trading at is $undefined, which is out of the analyst’s predicted range.